BIVI
BIOVIE INC.
NASDAQ · Healthcare · Biotechnology · US
$1.38
−5.48%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -26.0%
- EBIT
- -25.4%
- EPS
- +76.0%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- -28.8%
- EBIT
- -25.4%
- Net income
- -25.8%
- EPS
- +74.8%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026